Funding for this research was provided by:
Bristol-Myers Squibb
Pfizer
Article History
Accepted: 7 January 2021
First Online: 4 March 2021
Declarations
:
: The open access fee was funded by Bristol Myers Squibb and Pfizer. Funding of this study was provided by Bristol Myers Squibb and Pfizer.
: Steve Mayall and Imad Al-Dakkak were employees in the Development Consulting team at Pope Woodhead and Associates Ltd, UK (which is now part of Axian Consulting Ltd, UK) at the time of this research, which received funding from the Bristol Myers Squibb/Pfizer Alliance to conduct the study. Randip Kahlon and Sophie W Shen are employees of Bristol Myers Squibb with ownership of stocks in Bristol Myers Squibb. The authors have no other conflicts of interest regarding the contents of this article.
: Ethics Committee approvals for patient participation in the study were obtained as needed, according to local requirements. Informed consent was obtained from individual participants.
: This study is registered on ExternalRef removed with identifier NCT02339818.
: Not applicable.
: All authors contributed, critically reviewed drafts of the manuscript and approved the final version.